As President, CEO and Co-Founder, Dr. Sullivan is actively involved in charting the vision of the organization and working directly with the scientific and technical staff
to develop new, innovative products using the DiversitAb™ Platform. He has worked to form strategic partnerships around the world to promote the development of life saving therapeutics.
As a seasoned biotechnology executive, Dr. Sullivan has more than 15 years of leadership experience including President of a subsidiary of Kyowa Hakko Kirin,
a Japanese pharmaceutical company. During that time, he led initiatives to develop infectious disease, cancer and autoimmune therapeutics. Raising over $190M in capital to develop biopharmaceutical platform technologies, he has also led several mergers and acquisitions. Dr. Sullivan was previously Vice President of Business Development and Government Relations of Sanford Applied Biosciences, a subsidiary of Sanford Health. He was also the head of Genemark, a company developing molecular diagnostic tools to the animal health industry as well as a
co-founder of BioDak, a biotechnology development company.
Dr. Sullivan has been a thought leader in this field and worked with various committees and discussion groups that have focused on animal biotechnology and has actively participated in discussions for establishing a regulatory framework for this technology. He serves on the Executive Committee of the Board of Directors of the Biotechnology Industry Organization (BIO) in Washington, D.C. He is also Founder and Past President of the state affiliate of BIO, South Dakota Biotech.
He was appointed by the Governor of South Dakota to the state’s Research Commercialization Council and serves as Chairman of the South Dakota National Science Foundation EPSCoR.
Dr. Sullivan holds an undergraduate degree from the University of Arizona and graduate degrees from Brigham Young University, Kennedy-Western University,
and Utah State University in both reproduction and business.